8-K: KALA BIO Reports Q1 2024 Financial Results and Provides Corporate Update

KALA BIO announced its first quarter 2024 financial results, highlighting progress in its clinical trials and providing a corporate update.

Summary

• KALA BIO reported its financial results for the first quarter of 2024, ending March 31, 2024.
• The company is focused on advancing its clinical program for KPI-012 in Persistent Corneal Epithelial Defect (PCED).
• Patient enrollment is ongoing in the Phase 2b CHASE trial for KPI-012, with topline data expected by the end of 2024.
• KALA is also exploring the potential of KPI-012 for other corneal diseases, such as Limbal Stem Cell Deficiency (LSCD), and KPI-014 for rare inherited retinal diseases.
• The company had $48.5 million in cash and cash equivalents as of March 31, 2024.
• KALA anticipates its current cash resources, along with expected funding from a CIRM award, will fund operations into the third quarter of 2025.
• General and administrative expenses for the quarter were $5.4 million, compared to $6.0 million in the same period of 2023.
• Research and development expenses were $6.4 million, compared to $4.0 million for the same period in 2023.
• The net loss for the quarter was $11.8 million, or $4.20 per share, compared to a net loss of $14.5 million, or $6.99 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, the strong cash position, and the improved net loss per share. However, the increased R&D expenses and operating loss temper the overall positive outlook.

Positives

• The company has a strong cash position of $48.5 million, expected to fund operations into Q3 2025.
• Net loss per share improved from $6.99 to $4.20 year-over-year.
• Patient enrollment is ongoing in the Phase 2b CHASE trial for KPI-012.
• KALA is exploring multiple potential applications for its MSC-S platform technology.
• The company is targeting topline data from the CHASE trial by year-end 2024, which could serve as the first of two pivotal trials for BLA submission.

Negatives

• The company experienced an operating loss of $11.9 million for the quarter.
• Research and development expenses increased significantly to $6.4 million.
• Cash and cash equivalents decreased from $50.9 million at the end of 2023 to $48.5 million as of March 31, 2024.

Risks

• The company's ability to comply with the requirements of the CIRM award is a risk.
• There are uncertainties inherent in the initiation and conduct of clinical trials.
• The availability and timing of data from clinical trials are uncertain.
• Regulatory review of clinical trials and marketing approvals are subject to uncertainties.
• The company's ability to retain and hire key personnel is a risk.
• KALA needs to comply with the covenants under its loan agreement, including maintaining its Nasdaq listing.
• The company may need additional financing in the future.

Future Outlook

KALA anticipates that its current cash resources, along with expected funding from a CIRM award, will enable it to fund operations into the third quarter of 2025. The company is targeting topline data from the Phase 2b CHASE trial by year-end 2024 and is exploring additional indications for its platform technology.

Management Comments

• Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, stated that the company is acutely focused on advancing its clinical program for KPI-012 in PCED.
• Mr. Iwicki believes KPI-012 has the potential to address multiple impaired corneal healing processes that cause PCED.
• Mr. Iwicki also mentioned the company's commitment to exploring the potential of its platform technology more broadly.

Industry Context

KALA BIO is operating in the biopharmaceutical industry, specifically focusing on rare and severe eye diseases. The company's focus on mesenchymal stem cell secretome therapy positions it in an emerging field with potential for significant growth. The development of treatments for PCED and LSCD addresses unmet medical needs in the ophthalmology space.

Comparison to Industry Standards

• KALA BIO's focus on rare ocular diseases aligns with a growing trend in the biopharmaceutical industry, where companies are increasingly targeting niche markets with high unmet needs.
• The company's approach using mesenchymal stem cell secretome (MSC-S) platform is innovative, but it is still in the early stages of clinical development compared to more established therapies.
• Competitors in the ophthalmology space include companies like REGENXBIO and Adverum Biotechnologies, which are focused on gene therapies for retinal diseases, while KALA is focused on secretome-based therapies.
• KALA's cash runway into Q3 2025 is a positive sign, but it will need to continue to raise capital to fund its clinical programs, similar to other clinical-stage biotech companies.
• The company's R&D expenses are increasing as it advances its clinical programs, which is typical for companies in this stage of development.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the improved net loss per share.
• Employees may be impacted by the increased R&D activities and the company's focus on clinical development.
• Patients with PCED and other rare eye diseases may benefit from the potential development of new therapies.
• Creditors may be reassured by the company's strong cash position and expected funding into Q3 2025.

Next Steps

• KALA will continue patient enrollment in the Phase 2b CHASE trial for KPI-012.
• The company will target topline data from the CHASE trial by year-end 2024.
• KALA will continue to explore the potential of KPI-012 for other corneal diseases and KPI-014 for rare inherited retinal diseases.
• The company will continue to advance its preclinical studies for KPI-014.

Key Dates

Keywords

KALA BIO, KPI-012, PCED, MSC-S, Clinical Trial, Ocular Diseases, Biopharmaceutical, Retinal Diseases, CHASE Trial, Orphan Drug